{"id":232150,"date":"2026-04-07T10:49:00","date_gmt":"2026-04-07T14:49:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/04\/07\/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis\/"},"modified":"2026-04-07T11:00:17","modified_gmt":"2026-04-07T15:00:17","slug":"gilead-outlays-5bn-to-acquire-adc-specialist-tubulis","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/04\/07\/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis\/","title":{"rendered":"Gilead outlays $5bn to acquire ADC specialist Tubulis"},"content":{"rendered":"<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis\/\">Gilead outlays $5bn to acquire ADC specialist Tubulis<\/a><\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis\/\">https:\/\/www.pharmaceutical-technology.com\/news\/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-04-07 10:49:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.pharmaceutical-technology.com\">www.pharmaceutical-technology.com<\/a><\/p>\n<p>                                    The Tubulis acquisition represents another major expansion into the ADC market made by Gilead in the past decade. Credit: Sundry Photography\/Shutterstock.com.  <\/p>\n<p class=\"drop-cap\">Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company\u2019s recent string of high-profile M&#038;A activity in 2026.<\/p>\n<p>As per the agreement, Gilead will pay $3.15bn upfront and up to $1.85bn in milestones to buy the German biotech. Following the transaction\u2019s close, set for Q2 2026, Tubulis will become an ADC research organisation within Gilead.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/GMS-logo.svg\" alt=\"\"\/><\/p>\n<h4> Discover B2B Marketing That Performs <\/h4>\n<p>\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n<p>\n\t\t\t\t\t\t\tFind out more <span><\/span><\/p>\n<p>Tubulis\u2019 catalogue of drugs is headed by TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC that is currently in Phase Ib\/II trials for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). The asset produced positive safety and efficacy results in the former indication in early data shared in October 2025. Gilead will also acquire TUB-030, a 5T4 targeted ADC for solid tumour treatment, as well as other assets that are being developed for undisclosed cancer indications. \u00a0\u00a0<\/p>\n<p>Gilead\u2019s CEO Daniel O\u2019Day said: \u201cThe agreement to acquire Tubulis is a significant milestone in Gilead\u2019s progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a&#8230;<\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis\/\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead outlays $5bn to acquire ADC specialist Tubulis https:\/\/www.pharmaceutical-technology.com\/news\/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis\/ Publish Date: 2026-04-07 10:49:00 Source Domain:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":232151,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.pharmaceutical-technology.com\/wp-content\/uploads\/sites\/24\/2026\/04\/shutterstock_1671396043.jpg","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-232150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/232150"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=232150"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/232150\/revisions"}],"predecessor-version":[{"id":232152,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/232150\/revisions\/232152"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/232151"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=232150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=232150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=232150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}